Brainstorm Cell Therapeutics Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BCLI Over the counter 2834 www.brainstorm-cell.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Brainstorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine - Jun 2nd, 2026 7:00 am
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors - May 28th, 2026 5:45 am
BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market - May 19th, 2026 6:00 am
BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update - May 15th, 2026 2:05 pm
BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update - Mar 31st, 2026 2:01 pm
Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February - Feb 26th, 2026 4:22 am
Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market - Feb 20th, 2026 4:00 am
Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - Feb 19th, 2026 1:30 am
BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 14th, 2025 2:30 pm
BCLI: Focused on Initiation of Phase 3b ENDURANCE Trial of NurOwn® in ALS… - Aug 15th, 2025 7:22 am
BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update - Aug 14th, 2025 5:00 am
BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update - Aug 8th, 2025 5:00 am
BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB - Jul 17th, 2025 2:30 pm
FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness - Jul 8th, 2025 5:00 am
BCLI: Citizen’s Petition Filed Requesting the FDA Approve NurOwn™… - Jul 7th, 2025 5:12 am